BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22084895)

  • 1. Persistence with biologic therapies in the Medicare coverage gap.
    Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
    Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Part D plan enrollment by uninsured medicare beneficiaries.
    Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
    Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.
    Nair KV; Frech-Tamas F; Jan S; Wolfe P; Allen RR; Saseen JJ
    J Health Care Finance; 2011; 38(2):38-53. PubMed ID: 22372031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
    Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
    Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Part D coverage gap and adherence to diabetes medications.
    Gu Q; Zeng F; Patel BV; Tripoli LC
    Am J Manag Care; 2010; 16(12):911-8. PubMed ID: 21348561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
    Lundy J; Craig BM
    Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insurance coverage and health care use among near-elderly women.
    Xu X; Patel DA; Vahratian A; Ransom SB
    Womens Health Issues; 2006; 16(3):139-48. PubMed ID: 16765290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
    Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
    Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.